Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
PersonGen BioTherapeutics (Suzhou) Co., Ltd. clinical trials
The registry lists 43 studies whose lead sponsor is PersonGen BioTherapeutics (Suzhou) Co., Ltd.. 17 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 6, 2026.
Keep track of what changes. Save the PersonGen BioTherapeutics (Suzhou) Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesWhere
- China
- 41
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to PersonGen BioTherapeutics (Suzhou) Co., Ltd..
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.43 studiesSame company
Something wrong?
Focus areas
Conditions PersonGen BioTherapeutics (Suzhou) Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 43 of 43.
- PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/LymphomaRecruitingNCT07188610Phase 2
- Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/LymphomaNot yet recruitingNCT07623681Phase 1
- Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic MalignanciesRecruitingNCT07338604Early Phase 1
- Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid MalignanciesRecruitingNCT07312630Early Phase 1
- Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid MalignanciesRecruitingNCT07284927Phase 1
- Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.Not yet recruitingNCT06982534Early Phase 1
- Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 InjectionNot yet recruitingNCT06982547Early Phase 1
- UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.RecruitingNCT06092047Early Phase 1
- Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT06970951Early Phase 1
- Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune DiseasesNot yet recruitingNCT06871644Not applicable
- Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT06417398Early Phase 1
- Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune DiseasesRecruitingNCT06361745Not applicable
- UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT06279026Not applicable
- TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory NeuroblastomaRecruitingNCT05562024Phase 1
- UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05731219Phase 1
- TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05432401Early Phase 1
- TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid LeukemiaRecruitingNCT05017883Not applicable
- Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownNCT05722171Early Phase 1
- PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic MalignanciesStatus unknownNCT05170568Phase 1
- A Clinical Trial of TAA06 Injection in Advanced Solid TumorsStatus unknownNCT05190185Phase 1
- Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid TumorStatus unknownNCT04864821Early Phase 1
- TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid LeukemiaStatus unknownNCT04692948Not applicable
- CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant TumorsStatus unknownNCT04702841Early Phase 1
- CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological MalignanciesStatus unknownNCT04700319Early Phase 1
- CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute LeukemiaStatus unknownNCT04785833Not applicable
- CAR-T for r/r Malignant Tumors in ChildrenStatus unknownNCT04691349Early Phase 1
- γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue RelapseStatus unknownNCT04439721Early Phase 1
- CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label StudyStatus unknownNCT04480788Phase 1
- CD276 CAR-T for Patients With Advanced CD276+ Solid TumorsStatus unknownNCT04691713Not applicable
- Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen ReceptorCompletedNCT04650724Early Phase 1
- CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic LeukemiaStatus unknownNCT04004637Phase 1
- CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's LymphomaStatus unknownNCT04237428Not applicable
- Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple MyelomaStatus unknownNCT04186052Early Phase 1
- The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological MalignanciesStatus unknownNCT04184414Early Phase 1
- A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT03999697Phase 1
- CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/2
- CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AMLStatus unknownNCT02944162Phase 1/2
- CAR-T Cell Immunotherapy in MUC1 Positive Solid TumorStatus unknownNCT02617134Phase 1/2
- PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and LymphomaStatus unknownNCT02892695Phase 1/2
- CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid TumorStatus unknownNCT02839954Phase 1/2
- Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid TumorStatus unknownNCT02587689Phase 1/2
- CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02819583Phase 1/2
- Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT02851589Phase 1/2